ImpediMed Ltd
ASX:IPD
Gross Margin
ImpediMed Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
ImpediMed Ltd
ASX:IPD
|
81m AUD |
88%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
228.5B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
180.6B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
147.4B USD |
68%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
144B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
114B USD |
66%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
65.7B USD |
45%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
56.1B EUR |
38%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
42.4B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
274B CNY |
64%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
36.3B USD |
42%
|
ImpediMed Ltd
Glance View
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on ImpediMed Ltd's most recent financial statements, the company has Gross Margin of 87.9%.
You don't have any saved screeners yet